Press-release for stocks publishing date 2021 - 12 - 13 in the health technology sector

Prices are updated after-hours

publishing date : 2021 - 12 - 13 sector : Health technology

save search

First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
Published: 2021-12-13 (Crawled : 13:27) - alteritytherapeutics.com
ATHE | $2.13 130

Health Technology

| -76.05% | O: 0.24% H: 3.2% C: 0.42%
ath434 phase 2 trial authorization

Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang
Published: 2021-12-13 (Crawled : 20:20) - ir.zosanopharma.com
ZSAN | $0.5576 7.23% -5.85%

Health Technology

| -97.12% | O: -0.54% H: 1.45% C: -0.96%
pharma

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
Published: 2021-12-13 (Crawled : 01:00) - prnewswire.com
GNMSF | News | $290.34 0.23% 0

Health Technology

| -21.98% | O: -3.62% H: 5.16% C: 4.16%
JNJ | News | $147.07 -1.67% 890K

Health Technology

| -9.34% | O: 1.9% H: 0.0% C: 0.0%
GMAB | News | $28.545 -0.05% 36K

Health Technology

| -25.16% | O: -4.01% H: 1.01% C: -2.07%
AMGN | News | $270.69 -1.04% 120K

Health Technology

| 29.73% | O: 0.22% H: 1.65% C: 1.15%
treatment antibody

Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 01:00) - globenewswire.com
AGIO | $31.81 5.3% 5.06% 0

Health Technology

| 6.89% | O: 5.24% H: 4.95% C: 2.91%
transfusion

New Long-Term Results for GIVLAARI® (givosiran) Presented at ASH Annual Meeting & Exposition
Published: 2021-12-13 (Crawled : 00:00) - alnylam.com
ALNY | $146.07 0.19% 0.18% 0

Health Technology

| -16.86% | O: 6.02% H: 2.03% C: -0.29%
givlaari results

Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
TRVN | $0.388 4.81% -2.27% 0

Health Technology

| -42.99% | O: 6.24% H: 0.0% C: 0.0%
trv045 diabetic diabetes

Teleflex Receives Reimbursement Approval for the UroLift® System in JapanWill expand patient access to breakthrough BPH treatment
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
TFX | $211.11 1.85% 0.0% 0

Health Technology

| -34.29% | O: -0.09% H: 0.0% C: 0.0%
urolift treatment approval

Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
SNDX | $20.97 0.05% -0.05% 0

Health Technology

| 19.15% | O: -6.48% H: 18.59% C: 10.02%
gment-101 als 613 trial phase 1 positive

Sigilon Therapeutics Announces Strategic Reprioritization
Published: 2021-12-13 (Crawled : 23:00) - globenewswire.com
SGTX | $22.47 -2.56% 0.0% 0

Health Technology

| 718.51% | O: 0.0% H: 3.56% C: -7.83%
therapeutics

Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual MeetingPreliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
BPTH | $2.73 1.68% 18K

Health Technology

| -42.27% | O: -9.01% H: 0.0% C: 0.0%
ema phase 2 ongoing risk aml

Freeline Announces 2022 Corporate Priorities and Guidance
Published: 2021-12-13 (Crawled : 23:00) - globenewswire.com
FRLN | $6.48 0.0% 0

Health Technology

| 172.27% | O: -3.36% H: 3.7% C: 0.0%

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
CMPS | $8.25 18K

Health Technology

| -68.74% | O: -5.04% H: 0.0% C: 0.0%
comp360 treatment positive therapy depression psilocybin

ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
ORIC | $8.67 -1.14% 10K

Health Technology

| -39.14% | O: 1.67% H: 0.0% C: 0.0%
oric-533 ema als potential

Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
FATE | News | $4.46 -1.76% 85K

Health Technology

| -90.76% | O: -0.1% H: 0.0% C: 0.0%
ft596 therapeutics phase 1 positive t-cell

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System
Published: 2021-12-13 (Crawled : 22:00) - poseida.com
PSTX | $2.135 -1.16% 20K

Health Technology

| -69.66% | O: -0.42% H: 0.0% C: -5.5%
als car-t trials trial clinical trials t-cell

Avanos Medical, Inc. Announces Agreement To Acquire OrthogenRx, Inc.
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
AVNS | $18.7 -0.32% 2.8K

Health Technology

| -36.58% | O: -0.78% H: 0.0% C: 0.0%

Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
GILD | $66.45 -0.87% 380K

Health Technology

| -4.49% | O: -0.09% H: 0.0% C: 0.0%
zuma-12 yescarta treatment risk t-cell

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K

Health Technology

| -95.52% | O: -4.19% H: 5.62% C: 0.63%
nasdaq

Clearside Biomedical Added to the Nasdaq Biotechnology Index
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
CLSD | News P | $1.41 2.92% 49K

Health Technology